Ionis Pharmaceuticals (NASDAQ: IONS) insider transactions
In the twelve months to 10 November 2026, executives and directors of Ionis Pharmaceuticals reported 109 open-market sales of 1,557,266 shares ($120.7m) and 2 open-market purchases of 20,000 shares ($1.1m), by 19 people, according to the Form 4 filings they submitted to the SEC.
Latest transactions
| Date | Insider | Role | Transaction | Shares | Price | Held after | Filing |
|---|---|---|---|---|---|---|---|
| 16 October 2026 | Swayze Eric | EVP Research | Open-market sale | −53 | $43.54 | 390 | Form 4 |
| 16 October 2026 | Devers Shannon L. | EVP, Chief Human Resources Ofc | Open-market sale | −1,357 | $43.54 | 17,811 | Form 4 |
| 15 October 2026 | Swayze Eric | EVP Research | Option exercise | +125 | — | 443 | Form 4 |
| 15 October 2026 | Devers Shannon L. | EVP, Chief Human Resources Ofc | Option exercise | +2,820 | — | 19,168 | Form 4 |
| 31 August 2026 | Birchler Brian | EVP, Corp and Development Ops | Other | +58 | $51.31 | 102,883 | Form 4 |
| 31 August 2026 | Monia Brett P | Chief Executive Officer | Other | +98 | $51.31 | 242,760 | Form 4 |
| 31 August 2026 | O'neil Patrick R. | EVP CLO & General Counsel | Other | +63 | $51.31 | 59,205 | Form 4 |
| 31 August 2026 | Bennett C Frank | EVP, Chief Scientific Officer | Other | +110 | $51.31 | 60,128 | Form 4 |
| 31 July 2026 | Hayden Michael R | Director | Open-market purchase | +5,000 | $51.60 | 24,000 | Form 4 |
| 30 July 2026 | Hayden Michael R | Director | Open-market purchase | +15,000 | $53.38 | 19,000 | Form 4 |
| 15 July 2026 | Berthelsen Spencer R | Director | Option exercise | +5,220 | — | 161,233 | Form 4 |
| 15 July 2026 | Herman Joan E | Director | Option exercise | +5,220 | — | 51,306 | Form 4 |
| 7 July 2026 | Kordasiewicz Holly B. | EVP, Chief Development Officer | Open-market sale, 10b5-1 plan | −362 | $84.30 | 22,096 | Form 4 |
| 7 July 2026 | Diaz Allene M. | Director | Option exercise, 10b5-1 plan | +10,111 | $47.11 | 13,922 | Form 4 |
| 7 July 2026 | Diaz Allene M. | Director | Open-market sale, 10b5-1 plan | −10,111 | $85.42 | 3,811 | Form 4 |
| 7 July 2026 | Bennett C Frank | EVP, Chief Scientific Officer | Open-market sale, 10b5-1 plan | −5,536 | $83.58 | 75,018 | Form 4 |
| 7 July 2026 | Bennett C Frank | EVP, Chief Scientific Officer | Other, 10b5-1 plan | +15,000 | — | 15,000 | Form 4 |
| 7 July 2026 | Bennett C Frank | EVP, Chief Scientific Officer | Open-market sale, 10b5-1 plan | −15,000 | $85.46 | 0 | Form 4 |
| 1 July 2026 | Klein Joseph Iii | Director | Option exercise, 10b5-1 plan | +11,518 | $39.94 | 22,532 | Form 4 |
| 1 July 2026 | Klein Joseph Iii | Director | Open-market sale, 10b5-1 plan | −99 | $79.45 | 22,433 | Form 4 |
Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.
How to read the table
Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.
Where each row comes from
From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Ionis Pharmaceuticals page; the method, in data sources.
Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.